|
You are here: Home: BCU 6|2002:Daniel
F Hayes, MD: Select publications
Estrogen receptor biology and mechanisms for the
development of resistance to endocrine therapy
Atanaskova N et al. MAP kinase/estrogen receptor cross-talk
enhances estrogen-mediated signaling and tumor growth but does not
confer tamoxifen resistance. Oncogene 2002;21:4000-8. Abstract
Berry DA et al. HER-2/neu and p53 expression versus tamoxifen
resistance in estrogen receptorpositive, node-positive breast cancer.
J Clin Oncol 2000;18:3471-9. Abstract
Bieche I et al. ERBB2 status and benefit from adjuvant
tamoxifen in ERalpha-positive postmenopausal breast carcinoma.
Cancer Lett 2001;174:173-8. Abstract
Brinkman A et al. BCAR1, a human homologue of the adapter
protein p130Cas, and antiestrogen resistance in breast cancer cells.
J Natl Cancer Inst 2000;92:112-20. Abstract
Brockdorff BL et al. Increased expression of cytochrome
p450 1A1 and 1B1 genes in anti-estrogenresistant human breast cancer
cell lines. Int J Cancer 2000;88:902-6. Abstract
Campbell RA et al. Phosphatidylinositol 3-kinase/AKT-mediated
activation of estrogen receptor alpha: A new model for anti-estrogen
resistance. J Biol Chem 2001;276:9817-24. Abstract
Cheung KL et al. Selection of primary breast cancer patients
for adjuvant endocrine therapy--is oestrogen receptor alone adequate?
Breast Cancer Res Treat 2001;65(2):155-62. Abstract
Chung YL et al. Resistance to tamoxifen-induced apoptosis
is associated with direct interaction between Her2/neu and cell
membrane estrogen receptor in breast cancer. Int J Cancer
2002;97:306-12. Abstract
Clarke R et al. Molecular and pharmacological aspects
of antiestrogen resistance. J Steroid Biochem Mol Biol
2001;76:71-84. Abstract
Donovan JC et al. Constitutive MEK/MAPK activation leads
to p27(Kip1) deregulation and antiestrogen resistance in human breast
cancer cells. J Biol Chem 2001;276:40888-95. Abstract
Dorssers LC et al. Tamoxifen resistance in breast cancer:
Elucidating mechanisms. Drugs 2001;61:1721-33. Abstract
Dowsett M et al. HER-2 amplification impedes the antiproliferative
effects of hormone therapy in estrogen receptor-positive primary
breast cancer. Cancer Res 2001;61:8452-8. Abstract
Geisler J, Lonning PE. Resistance to endocrine therapy
of breast cancer: Recent advances and tomorrow's challenges.
Clin Breast Cancer 2001;1:297-308; discussion 309. Abstract
Goss PE, Strasser K. Tamoxifen resistant and refractory
breast cancer: The value of aromatase inhibitors. Drugs
2002;62:957-66. Abstract
Graham JD et al. Nuclear receptor conformation, coregulators,
and tamoxifen-resistant breast cancer. Steroids 2000;65:579-84.
Abstract
Graham JD et al. Thoughts on tamoxifen resistant breast
cancer. Are coregulators the answer or just a red herring?
J Steroid Biochem Mol Biol 2000;74:255-9. Abstract
Gu Z et al. Association of interferon regulatory factor-1,
nucleophosmin, nuclear factor-kappaB, and cyclic AMP response element
binding with acquired resistance to Faslodex (ICI 182,780). Cancer
Res 2002;62:3428-37. Abstract
Hori M et al. Overexpression of mitogen-activated protein
kinase superfamily proteins unrelated to Ras and AF-1 of estrogen
receptor alpha mutation in advanced stage human breast cancer. Pathol
Res Pract 2000;196:817-26. Abstract
Kato S. Estrogen receptor-mediated cross-talk with growth
factor signaling pathways. Breast Cancer 2001;8:3-9. Abstract
Kenny FS et al. Change in expression of ER, bcl-2 and
MIB1 on primary tamoxifen and relation to response in ER positive
breast cancer. Breast Cancer Res Treat 2001;65(2):135-44.
Abstract
Knoop AS et al. Value of epidermal growth factor receptor,
HER2, p53, and steroid receptors in predicting the efficacy of tamoxifen
in high-risk postmenopausal breast cancer patients. J Clin
Oncol 2001;19:3376-84. Abstract
Kunisue H et al. Anti-HER2 antibody enhances the growth
inhibitory effect of anti-oestrogen on breast cancer cells expressing
both oestrogen receptors and HER2. Br J Cancer 2000;82:46-51.
Abstract
Kurokawa H, Arteaga CL. Inhibition of erbB receptor (HER)
tyrosine kinases as a strategy to abrogate antiestrogen resistance
in human breast cancer. Clin Cancer Res 2001;7:4436s-4442s;
discussion 4411s-4412s. Abstract
Kurokawa H et al. Inhibition of HER2/neu (erbB-2) and
mitogen-activated protein kinases enhances tamoxifen action against
HER2-overexpressing, tamoxifen-resistant breast cancer cells.
Cancer Res 2000;60:5887-94. Abstract
Lee AV et al. Cross-talk among estrogen receptor, epidermal
growth factor, and insulin-like growth factor signaling in breast
cancer. Clin Cancer Res 2001;7:4429s-4435s; discussion
4411s-4412s. Abstract
Lee ES et al. Cross-resistance of triphenylethylene-type
antiestrogens but not ICI 182,780 in tamoxifen-stimulated breast
tumors grown in athymic mice. Clin Cancer Res 2000;6:4893-9.
Abstract
Levenson AS et al. Control of the estrogen-like actions
of the tamoxifen-estrogen receptor complex by the surface amino
acid at position 351. J Steroid Biochem Mol Biol 2001;76:61-70.
Abstract
Leveque J et al. Benefits of complete polyamine deprivation
in hormone responsive and hormone resistant MCF-7 human breast adenocarcinoma
in vivo. Anticancer Res 2000;20:97-101. Abstract
McClelland RA et al. Enhanced epidermal growth factor
receptor signaling in MCF7 breast cancer cells after long-term culture
in the presence of the pure antiestrogen ICI 182,780 (Faslodex).
Endocrinology 2001;142:2776-88. Abstract
Nichols M, McCarty KS Jr. Functional mutations of estrogen
receptor protein: Assay for detection. Breast Cancer Res
Treat 2002;72:61-8. Abstract
Nicholson RI et al. Modulation of epidermal growth factor
receptor in endocrine-resistant, oestrogen receptor-positive breast
cancer. Endocr Relat Cancer 2001;8:175-82. Abstract
Osborne CK et al. Estrogen receptor: Current understanding
of its activation and modulation. Clin Cancer Res 2001;7:4338s-4342s;
discussion 4411s-4412s. Abstract
Santen R et al. Adaptive hypersensitivity to estradiol:
Potential mechanism for secondary hormonal responses in breast cancer
patients. J Steroid Biochem Mol Biol 2001;79(1-5):115-25.
Abstract
Speirs V, Kerin MJ. Prognostic significance of oestrogen
receptor beta in breast cancer. Br J Surg 2000;87:405-9.
Abstract
Wakeling AE et al. Prospects for combining hormonal and
nonhormonal growth factor inhibition. Clin Cancer Res 2001;7:4350s-4355s;
discussion 4411s-4412s. Abstract
Yoshida T et al. Distinct mechanisms of loss of estrogen
receptor alpha gene expression in human breast cancer: Methylation
of the gene and alteration of transacting factors. Carcinogenesis
2000;21:2193-201. Abstract
|
